Search Results

You are looking at 81 - 90 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

Presented by: Patrick A. Brown

relapsed or refractory disease, various salvage therapies are available, but immunotherapies have produced a paradigm shift in response rates. At the NCCN 2020 Virtual Congress: Hematologic Malignancies, Patrick A. Brown, MD, Professor of Oncology, The

Full access

New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma

Presented by: Michael K. Gibson

, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, and member of the NCCN Guidelines Panel for Esophageal/Gastric Cancers. Now, the addition of immunotherapy to chemotherapy in the frontline setting has led to a survival benefit in 3 large randomized

Full access

Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma

Presented by: Rajiv Agarwal and Lea K. Matsuoka

Moderated by: Daniel B. Brown

. Agarwal commented. “Currently, there are no definitive data to support the use of systemic therapy [with tyrosine kinase inhibitors or immunotherapy] as a bridge to transplantation or as neoadjuvant therapy prior to resection.” Multiple ongoing studies are

Full access

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

Jae Park

T-cell engagement has led to key breakthroughs in the management of recurrent acute lymphoblastic leukemia (ALL). Despite these novel immunotherapies, however, up to 80% of adult patients still die of the disease with or without hematopoietic stem

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes

who are eligible for newer targeted therapies or immunotherapies are now surviving longer, with 5-year survival rates ranging from 15% to 50%, depending on the biomarker. 3 – 13 These NCCN Guidelines Insights focus on recent updates in targeted

Full access

PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, and May T. Cho

and effectively treated with an ICI. We also review the literature on immunotherapy use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. Case Presentation A 61-year-old man with

Full access

Multidisciplinary Management of Advanced Kidney Cancer

Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff

sunitinib and showed an overall survival benefit for the immunotherapy combination in intermediate- and poor-risk patients with metastatic RCC. 3 At 30 months, overall survival was 60% versus 47% for sunitinib in intermediate- and poor-risk patients, but no

Full access

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Mitul Gandhi and Adam Petrich

exists that immunotherapy may heighten the already elevated risk of PML in patients with HIV, although a recent analysis suggests incidence is rare. 27 Notably, neither of the present patients has developed signs or symptoms suggestive of PML several

Full access

Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

this regimen over sorafenib. Sorafenib and lenvatinib each remain standard first-line options, and multiple other vascular endothelial growth factor (VEGF)–directed therapies and immunotherapies represent options in subsequent lines. Liver function and

Full access

Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers

Presented by: Jaffer A. Ajani and Katrina S. Pedersen

still hurdles” in the treatment of MSI-H/dMMR tumors with immunotherapy, one being the development of resistance, Dr. Ajani continued. The tumor cell antigen can become downregulated, so even though activated, the T cell cannot find the target and will